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ABSTRACT  11 
The poor solubility of curcumin (CURC) in aqueous media leads to a low bioavailability, which 12 
prevents its application in pharmaceutical formulations. In this work, the Supercritical Antisolvent 13 
process (SAS) was used to produce coprecipitates of CURC and poly (vinyl pyrrolidone) (PVP) from 14 
mixtures of ethanol and acetone. The effects of operating parameters: pressure, temperature, solution 15 
concentration, drug/polymer mass ratio and solution flow rate were analysed for a 70-30 (v/v) 16 
acetone-ethanol mixture. It was found that the composition of acetone in the solvent mixture is the 17 
parameter that affects particle size and curcumin recovery the most. The thermal behaviour, 18 
crystallinity, molecular interactions, apparent solubility, release profile of the coprecipitates and 19 
possible degradation of curcumin were investigated. The results showed that the SAS process is 20 
effective in preparing amorphous formulations of CURC/PVP with an apparent solubility of more 21 
than 600 times higher than that of the physical mixture of the raw compounds. 22 
Keywords: coprecipitation; curcumin; PVP; supercritical antisolvent process; dissolution 23 
1. Introduction 24 
Curcumin (CURC) is a polyphenolic hydrophobic compound extracted from the roots of Curcuma 25 
longa and traditionally used as a spice and food additive. It has been demonstrated that curcumin has 26 
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a wide range of therapeutic properties such as anticancer, antioxidant, antimicrobial and anti-27 
inflammatory [1,2]. However, the use of curcumin in drug formulations is still not approved by the 28 
Food and Drug Administration (FDA), limited by several reasons including its low oral bioavailability 29 
caused by its poor solubility in aqueous media, low absorption and fast intestinal metabolism. In 30 
addition, curcumin undergoes degradation under light, heat and alkaline pH [3,4].  31 
In recent decades, several curcumin formulations have been developed to address these issues 32 
including nanoparticles, liposomes, polymeric micelles, dendrimers and hydrogels [5–7]. The 33 
coprecipitation of active pharmaceutical ingredients (API) with hydrophilic polymers is advantageous 34 
because it can improve the API dissolution properties while protecting it against degradation. 35 
Poly(vinyl pyrrolidone) (PVP) was selected in this work because it is a biodegradable polymer 36 
approved as an inactive ingredient by the FDA and hence widely used in pharmaceutical applications. 37 
Several studies have demonstrated its ability in modifying the crystallisation kinetics of poorly water-38 
soluble compounds by producing amorphous formulations with improved dissolution profile [8–10]. 39 
PVP is also expected to inhibit drug recrystallisation in the gastro-intestinal tract after oral 40 
administration [11,12], giving time for drug molecules to be absorbed into the systemic circulation, 41 
thus increasing its bioavailability [13].  42 
The preparation of solid dispersions of curcumin and PVP with different molecular weights has been 43 
reported using conventional micronization techniques, such as spray drying [14] and solvent 44 
evaporation [15–17]. These methods have disadvantages such as the use of high temperature, which 45 
causes the degradation of thermo-sensitive compounds, low yields and high residual solvent content 46 
in the formulation, often requiring an extra processing step. Moreover, the control of particle 47 
morphology, particle size and size distribution is difficult [18–20]. In smaller quantities, PVP has 48 
been used as a stabilizer for curcumin nanoparticles prepared via liquid antisolvent methods followed 49 
by freeze drying [21–23].   50 
Supercritical fluids (SCFs) are attractive for particle precipitation as they combine liquid-like 51 
properties, such as high solvation power, and gas-like properties, including high diffusivity and 52 
compressibility. SCF-based micronization has demonstrated advantages over conventional techniques 53 
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since particle size can be controlled through the manipulation of the operating parameters, the use of  54 
relatively low temperatures and formulations with low or no residual solvent can be obtained [24,25]. 55 
Carbon dioxide is a usual choice for SCF-based micronization processes since it is inexpensive, non-56 
toxic, non-flammable, environmentally benign and it has a relatively low critical pressure (7.39 MPa) 57 
and critical temperature (31.1°C). Depending on the role played by the supercritical carbon dioxide 58 
(sc-CO2) in relation to the solute, it can act as solvent, co-solute, antisolvent, dispersing agent, 59 
plasticizer or reaction medium.  60 
In the Supercritical Antisolvent (SAS) process, the solute is typically dissolved in an organic solvent 61 
and then sprayed into a high pressure vessel through which sc-CO2 is passed continuously. The 62 
instantaneous diffusion of sc-CO2 into the liquid solution and, in minor extent, the evaporation of the 63 
liquid to the supercritical phase leads to the supersaturation of the liquid solution and precipitation of 64 
the solute, which is collected on a filter. Solvent and antisolvent are then separated via simple 65 
depressurization in a separator located downstream the precipitation vessel [26]. Although studied for 66 
many years, the SAS process is still not widely used in the pharmaceutical industry. A deeper 67 
understanding of the phenomena involved in each step is required to allow the selection of the most 68 
appropriate operating conditions and enable process control. Extensive use of SAS at industrial scale 69 
to process pharmaceutical and food ingredients is believed likely in the future, especially due to the 70 
need of finding more environmentally friendly technologies as recently discussed [27]. A key feature 71 
of SAS is its ability to process a wide variety of compounds to obtain several morphologies and sizes 72 
including crystals, nanoparticles, microparticles and expanded microparticles [28–30]. However, the 73 
use of SAS to produce coprecipitates has not always been successful. In some works, irregular and 74 
coalescing particles with wide particle size distribution [31] and low encapsulation efficiency [32] 75 
were obtained and the demonstration of an effective coprecipitation through the improvement of the 76 
drug dissolution properties is hardly reported [33].  77 
In our recent work, curcumin was simultaneously precipitated and coated on the surface of lactose 78 
particles by the integration of the SAS process with a fluidized bed under pressure (SAS-FB) to 79 
improve the flow properties of the formulation [25]. In this work, the aim is to improve also the 80 
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dissolution properties of curcumin through its coprecipitation with PVP by SAS, which is a suitable 81 
technique to treat thermo- and light-sensitive compounds, since low temperatures can be used and the 82 
experiments are carried out away from light.  83 
Other SCF-assisted processes have been used to produce CURC/PVP coprecipitates. Adami et al. [34] 84 
obtained spherical and collapsed particles with mean size ranging from 220 - 380 nm by the 85 
supercritical assisted atomization (SAA), using ethanol as solvent. The issue here is the use of high 86 
temperature (80 °C) since curcumin degradation is known to be  intensified above 60˚C [4,35]. The 87 
quantification of product recovery and possible degradation of curcumin were not presented by the 88 
authors. The atomized rapid injection solvent extraction (ARISE) method has also been applied for 89 
the coprecipitation of curcumin in ternary composites with PVP and cyclodextrins, with very few 90 
experiments being carried out with the binary CURC/PVP. As the intended application was 91 
pulmonary delivery, microparticles were produced and in some of the images presented it was 92 
possible to distinguish curcumin crystals in a porous structure, which indicate that the materials 93 
precipitated separately [36–38]. Although there are similarities between the SAS and ARISE 94 
processes in terms of the role of sc-CO2, differences between the mixing mechanism can lead to 95 
different results. The use of SAS process to produce CURC/PVP coprecipitates for pharmaceutical 96 
application has been reported once by Chhouk et al. [39]. They used a micro-swirl mixer, a patented 97 
device, to process curcumin and PVP from a 90-10 acetone-ethanol mixture. Highly coalescing 98 
nanoparticles (25 - 342 nm) were obtained while very relevant information such as total product 99 
recovery, curcumin recovery and drug dissolution kinetics was not presented. Only samples with low 100 
curcumin content (3-9%) were produced and no explanation was given for the selection of the solvent 101 
mixture used.  102 
Therefore, it is clear that a deeper study and understanding of the coprecipitation of curcumin and 103 
PVP by SAS is necessary, which is the aim of this work. We also want to test if it is possible to obtain 104 
non-coalescing nanoparticles of the composite material, with high curcumin content (up to 25%) and 105 
improved dissolution properties, without the aid of a complex mixing device, as reported in the 106 
aforementioned work [39]. For the first time, different organic solvent mixtures were studied to 107 
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understand how adjusting the solvent properties (solvation power) can modulate particle size and 108 
recovery of CURC/PVP coprecipitates. The effects of operating parameters, pressure, temperature, 109 
initial solution concentration, drug/polymer ratio and solution flow rate, were also investigated.  110 
2. Experimental 111 
2.1. Materials 112 
Curcumin (CURC, purity ≥ 90%) was purchased from Cayman Chemical and poly (vinyl pyrrolidone) 113 
(PVP, Mw = 10 kg/mol), sodium dodecyl sulphate (SDS) and acetic acid (glacial class 8, purity ≥  114 
99%) were purchased from Sigma Aldrich, UK and Ireland. Ethanol (EtOH, purity = 99.97%) and 115 
carbon dioxide (purity ≥ 99.8%) were purchased from VWR Chemicals and BOC, UK, respectively. 116 
Acetone (Ac, purity = 99.99%) and acetonitrile (purity = 99.99%) were purchased from Fisher 117 
Chemical, UK. All materials were used as-received. 118 
2.2. SAS equipment 119 
Fig. 1 shows the diagram of the SAS process. CO2 is delivered to the precipitator or high pressure 120 
vessel (HPV) by an air driven pump (PowerStar 4; Model: P464, Sprague). Before entering the pump, 121 
the CO2 line passes through a cold bath (Grant C1G) operated below 0°C to promote the condensation 122 
of CO2 and avoid pump cavitation. After the pump, the CO2 is heated in a hot water bath (Tecam open 123 
bath TECAM1 + Grant Type ZA Grant bridge control unit) to achieve the desired operating 124 
temperature and then it enters the precipitation vessel via a tube of 1/4 inch OD. The solvent/solution 125 
is delivered by an HPLC pump (Waters M-6000). Detail of the precipitation vessel and injection 126 
device can be seen in the supplementary material. A stainless steel capillary with internal diameter of 127 
100 µm, external diameter of 1/32 in and 20 cm in length (Thames Restek UK), placed concentric 128 
with the CO2 delivery tube, is used as a nozzle to promote the atomization of the solvent/solution,. 129 
The nozzle end, where the solution is sprayed out, is placed 2.4 mm lower than the end of CO2 inlet 130 
tube to avoid the partial blockage of the CO2 tube with polymer as observed in some preliminary 131 
experiments.  132 
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The high pressure vessel (HPV) used as precipitator is a 500 ml cylindrical jacketed autoclave 133 
(Baskerville Scientific, UK) containing three saphire windows. Hot water is continuously supplied to 134 
the heating jacket to keep the HPV at the desired operating temperature by the same heat exchanger 135 
used to heat up the CO2 line. The precise reading of the temperature and pressure inside the vessel is 136 
enabled by a thermocouple (RS PRO Type K) and pressure transducer (GE Druck PTX 1400) 137 
displayed in a digital process indicator (GE Druck DPI 282). The HPV is protected against 138 
overpressure by a safety valve (Swagelok SS-4R3A). Precipitated particles are collected by a 139 
cellulose thimble (43 mm x 123 mm, Whatman) installed inside the HPV, allowing the flow of CO2 + 140 
organic solvent mixture. The chamber pressure is controlled by a pressure regulator (Tescom 26-141 
1752-24) located in the by-pass of the CO2 pump. A middle pressure vessel (MPV) of approximately 142 
300 ml (Swagelok double-ended sample cylinder, 316L-HDF4-300-PD) is connected to the 143 
precipitator through a micrommetric valve (MMV) (Hoke 1335G4Y), which enables the manual 144 
control of the CO2 flow rate, which is displyed by a mass flow transmitter (Rheonik RHE08) placed in 145 
the CO2 inlet to the HPV. The MPV pressure is controlled by a pressure reducing regulator (GO BP3-146 
1A11I5J114) at around 1 MPa. It is also protected against overpressure by a safety valve (Swagelok 147 
SS-4R3A). Due to the pressure drop, the MPV enables the separation of the phases: the organic 148 
solution is condensed and collected in bottom of the vessel, while gaseous CO2 flows out from the 149 
top. The CO2 then passes through the pressure reducing regulator, decreases its pressure to ambient, 150 
enters a cyclone to remove fine droplets of solution possibly entrained in the gas phase and is finally 151 
directed to vent. A third heat exchanger and pump (Tecam circulator C-400) supply hot water through 152 
a flexible pipe which surrounds the MMV and MPV to avoid their freezing due to depressurization. 153 
Additional manometers (Budenberg 966GP) are placed in the outlet of the CO2 cylinder, outlet of the 154 
CO2 pump, inlet of the precipitation vessel and inlet of the MPV. 155 
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 156 
Fig. 1. SAS experimental setup. 157 
 158 
2.3. SAS experimental procedure 159 
Firstly, the precipitator is pressurized with CO2 until the desired pressure is achieved. At this point, 160 
the outlet micrometric valve (MMV) is opened to give a constant flow of sc-CO2 (40 g/min for all 161 
experiments), whilst maintaining pressure (Fig. 1).  162 
Solvent is then pumped into the precipitator through the 100 µm capillary nozzle for enough time to 163 
reach quasi-steady state composition of solvent and CO2, before the pump is switched to a solution of 164 
curcumin, PVP or curcumin and PVP. As the precipitation happens inside of the cellulose thimble and 165 
glass connector (dimensions shown in the supplementary material), rather than in the whole volume of 166 
the vessel, the mean residence time of the materials varies between 2 and 5 minutes, being close to 3 167 
minutes at 40°C and 9.0 MPa. Assuming the behaviour of an ideal stirred tank, at least three residence 168 
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times of CO2 and solvent were allowed to flow before the drug solution was injected so the 169 
CO2/solvent ratio in the vessel was at least 95% of the inlet composition. 170 
After the desired amount of curcumin and/or PVP has been injected into the precipitator (usually 400 171 
mg of solute in 40 ml of solution), the pump is reverted to solvent to purge the line (10 ml) and assure 172 
all the solution inside the dead volume has been delivered. Then the solvent pump is stopped and 173 
fresh CO2 runs through the system to remove any residual solvent. Finally, the pressure is gradually 174 
decreased to ambient, the thimble is removed from inside the high pressure vessel and then the 175 
powder is collected with a spatula. Some material remains entrapped in the pores of the thimble and 176 
therefore most, but not all, precipitated powder can be collected. No powder is found outside the 177 
thimble or inside the vessel, however possible loss of nanoparticles might occur in the first minutes of 178 
particle generation but it should stop as soon as the particles build up a filter cake. 179 
2.4. Preparation of the physical mixture 180 
Physical mixtures (PM) of curcumin (CURC) and PVP, obtained by shaking the powders in sealed 181 
vials for 5 minutes, were prepared with mass ratios of 1:3 and 1:10 CURC/PVP for comparison with 182 
equivalent SAS coprecipitated samples. 183 
2.5. Analyses 184 
2.5.1. Scanning electron microscopy (SEM) 185 
Scanning Electron Microscopy (SEM - model Philips XL-30 FEG) was used to observe the 186 
morphology and particle size of raw materials and coprecipitates at 10 kV and 10 mA. Samples were 187 
initially fixed on a double-sided adhesive carbon tape and sputter coated (Polaron SC 7640) with gold 188 
for 3 min at 25 mA. Image J analysis software was used to measure particle size and size distribution. 189 
Usually 500 particles of each sample in SEM images with different magnifications were accounted. 190 
The results are presented as mean diameter ± arithmetic standard deviation. 191 
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2.5.2. Total product recovery 192 
The total product recovery (Rec.) is an important parameter to assess the efficiency of a process. It 193 
was defined as the percentage ratio of the final mass of precipitates collected to the initial mass 194 
delivered to the precipitator, as shown below: 195 
𝑅𝑒𝑐. =  
𝑚𝑎𝑠𝑠 (𝐶𝑈𝑅𝐶 +  𝑃𝑉𝑃) 𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑒𝑑
𝑚𝑎𝑠𝑠 (𝐶𝑈𝑅𝐶 +  𝑃𝑉𝑃)𝑓𝑒𝑒𝑑
 × 100% 
2.5.3. Curcumin content and recovery 196 
Accurately weighed samples were dissolved in 50% v/v water-acetone solution and curcumin 197 
concentration was determined using an ultraviolet (UV)–visible spectrophotometer (Thermo Scientific 198 
Orion AquaMate) to measure the solution absorbance at λ = 425 nm. At this wavelength the 199 
absorbance of PVP is negligible (as reported in the supplementary material), while that of curcumin is 200 
proportional to its concentration (R
2
 = 0.999). All the measurements were taken within few minutes of 201 
sample dissolution so the effect of curcumin degradation in contact with water can be considered 202 
negligible. Each sample was analysed 3-5 times and the mean values are reported. Curcumin content 203 
(Cont.) was obtained by dividing the mass of curcumin in the analysed sample by the total sample 204 
mass, as follows: 205 
𝐶𝑜𝑛𝑡. =
𝐶𝑈𝑅𝐶 𝑚𝑎𝑠𝑠 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒
𝑡𝑜𝑡𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒 𝑚𝑎𝑠𝑠
× 100% 
Curcumin recovery (CURC Rec.) was calculated as shown below: 206 
𝐶𝑈𝑅𝐶 𝑅𝑒𝑐. =
𝑅𝑒𝑐.× 𝐶𝑜𝑛𝑡.
𝐶𝑈𝑅𝐶 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑓𝑒𝑒𝑑
 
The use of the cellulose thimble described here very conveniently facilitates the recovery of the 207 
powder without requiring the precipitator to be completely disassembled from the rig and cleaned 208 
after each run. The amount of curcumin retained in the pores of the cellulose thimble (filter) was 209 
quantified by washing each filter with a known volume of 50% v/v water-acetone and analysing the 210 
solution by (UV)–visible spectrophotometer.  211 
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2.5.4. High Performance Liquid Chromatography (HPLC) 212 
Raw curcumin and processed samples were analysed by HPLC to investigate possible degradation of 213 
curcumin after processing. A gradient elution was employed using an Accucore C18 column (30 mm 214 
x 2.1 mm, 2.6 µm, Thermo Scientific) starting with a mobile phase containing acetonitrile and 2% 215 
acetic acid initially at 10:90 (v/v). The proportion of the materials was gradually changed to 50:50 by 216 
10 minutes with each run lasting 16 minutes in total.  A flow rate of 0.85 mL/min, a column 217 
temperature of 30°C, a detection wavelength of 425 nm and an injection volume of 20 μL were 218 
employed [40]. Sample solutions were prepared in 50:50 acetonitrile-2% acetic acid and filtered with 219 
a 0.22 µm PTFE syringe filter prior to analyses. 220 
2.5.5. X-ray diffraction (XRD) 221 
Raw materials and coprecipitates were analysed by X-ray diffraction (XRD, Bruker D8, UK) at 40 kV 222 
and 30 mA to determine the degree of crystallinity before and after processing. Patterns were obtained 223 
with a beam angle varying from 5° to 40° and a step size of 0.023°. 224 
2.5.6. Differential Scanning Calorimetry (DSC) 225 
The thermal behaviour of the samples and unprocessed compounds were assessed by Differential 226 
Scanning Calorimetry (Discovery DSC 25, TA Instruments) working with a nitrogen purge of 50 227 
ml/min. A heat-cool-heat cycle  was employed to eliminate possible interference of moisture and 228 
relieve stress allowing a proper determination of the glass transition temperature (Tg) of the materials 229 
[41–43]. First, the samples were placed in aluminium pans and accurately weighed. A hole was made 230 
on each lid, allowing the removal of moisture with the purge gas. They were then heated from 50°C to 231 
160°C (above the glass transition of PVP and below the melting point of curcumin) at 20°C/min and 232 
after that quench cooled (100°C/min) to the initial temperature. Finally, they were heated to 250°C at 233 
20°C/min. The results presented correspond to the final heating stage in which the glass transition 234 
temperature, melting point and enthalpy of fusion were measured. TA Instruments Universal Analysis 235 
Software was used to estimate the glass transition temperature (Tg, midpoint of the change in heat 236 
capacity) and melting point (Tm, onset temperature) of the samples. 237 
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2.5.7. Fourier transform infrared spectroscopy (FTIR)  238 
Fourier transform infrared spectroscopy (FTIR, Jasco-6300) equipped with an attenuated total 239 
reflectance (ATR) accessory was used to analyse the chemical structure of coprecipitates and possible 240 
molecular interactions generated after processing. 64 scans were taken in a range of 800-4000 cm
-1
 241 
with a resolution of 4 cm
-1
 [44,45].  242 
2.5.8. Drug apparent solubility 243 
The apparent solubility of the materials was analysed by adding excess sample to 2 ml of distilled 244 
water and then sonicating the suspension at 25°C for 15 minutes. Then the suspension was filtered 245 
with a 0.22 µm PTFE syringe filter. Curcumin concentration was determined via UV–visible 246 
spectrophotometer. Experiments were performed in triplicates and the mean values are shown. 247 
2.5.9. In vitro dissolution studies 248 
In vitro dissolution studies were performed using a USP 2 dissolution apparatus (rotating paddles). 249 
Samples were accurately weighed with equivalent amount of curcumin (5 ppm) and incubated at 37 ± 250 
0.5°C in 200 mL of water and 0.25% w/v sodium dodecyl sulphate (SDS). The rotation of the paddles 251 
was set to 100 rpm.  2 mL of the solution was withdrawn at different time intervals and replaced with 252 
the same volume of fresh medium. Curcumin concentration was then analysed by UV–visible 253 
spectrophotometer. Curcumin release was calculated as follows: 254 
𝑅𝑒𝑙𝑒𝑎𝑠𝑒 (%) =  
𝑚𝑡
𝑚100%
× 100% 
where mt represents the mass of curcumin released at time t and m100% is the mass of curcumin at 255 
complete dissolution. The tests were performed in triplicates and the mean values are reported. 256 
3. Results and discussion 257 
In the SAS process, the selection of the operational conditions is crucial in the success of the 258 
precipitation [46,47]. Knowledge of thermodynamics, jet hydrodynamics, mass transfer and 259 
crystallization kinetics is required to properly understand the results. Supersaturation is the driving 260 
force for precipitation and can be defined as the ratio between the solute concentration in the solvent-261 
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CO2 system and the equilibrium concentration (solubility). Particle size is dependent on the degree of 262 
solution supersaturation achieved. High initial solution concentration and low equilibrium 263 
concentration of the solute in the fluid phase leads to high supersaturation. Additionally, the 264 
supersaturation can be affected by the flow rate of the materials used, responsible for the turbulence 265 
and mixing between the phases. The yield of precipitation is especially influenced by the 266 
concentration of solute present in the effluent solution [48–50]. 267 
For most experiments, pressure, temperature and CO2 flow rate were kept constant at 40°C, 9.0 MPa 268 
and 40 g/min, giving a CO2 molar fraction (XCO2) between 0.98 - 0.99. According to the literature 269 
[51], these conditions would ensure that the precipitation happens in the supercritical region of the 270 
mixed solvent-CO2. 271 
3.1. Precipitation of single compounds 272 
Prior to coprecipitation experiments, the compounds were processed separately to compare with their 273 
precipitation behaviour (morphology and size) when processed at the same conditions of the 274 
coprecipitates. This information is useful to evaluate the success of the coprecipitation and any 275 
possible changes in morphology that can occur when the two compounds are processed 276 
simultaneously.  277 
PVP is a biocompatible polymer commonly used in drug delivery applications and has been 278 
previously precipitated by SAS [24,52,53]. In this work, the experiments were carried out initially 279 
using ethanol as solvent, solution concentration of 10 mg/ml and solution flow rate of 1 ml/min, 280 
resulting in a CO2 molar ratio of XCO2 = 0.98.  281 
Table 1 summarises the operational conditions and the results obtained. In run #1 a negligible amount 282 
of powder was recovered. Since PVP is highly soluble in ethanol [24], the concentration used might 283 
have not been high enough to achieve the minimum supersaturation required for particle generation. 284 
In an attempt to increase the supersaturation, in run #2, the solution concentration was increased to 20 285 
mg/ml and the other parameters were kept constant; however this concentration was still not enough 286 
and the precipitation was again unsuccessful.  287 
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Another way to affect the supersaturation, while keeping the initial solution concentration constant, is 288 
by changing the solubility (equilibrium concentration) of the solute in the fluid phase. As the 289 
solubility of PVP in ethanol is much higher than in acetone (315 mg/ml versus 7 mg/ml), solvent 290 
mixtures of acetone-ethanol (Ac-EtOH) were used. As a consequence of the addition of a poor solvent 291 
to PVP (acetone), higher supersaturation levels can be achieved and a higher proportion of the solute 292 
precipitates, increasing product recovery. In fact, the addition of acetone into ethanol to produce a 293 
50% v/v mixture allowed a successful precipitation in run #3 and the increase in acetone content to 294 
90% v/v further improved PVP recovery in run #4 from 2.0 to 87.0% (Table 1). These results 295 
demonstrate the significant impact of changing the solute solubility in the fluid phase by the 296 
manipulation of the solvent power of the organic solution. Pure acetone was not used to process PVP 297 
since PVP solubility in acetone is below 10 mg/ml (approximately 7 mg/ml). 298 
The precipitation of PVP from acetone-ethanol mixtures has been previously investigated. However, 299 
contrary to what has been demonstrated here, De Marco et al. [24] reported a process yield of around 300 
90% for experiments with several acetone-ethanol mixture compositions, while Rossmann et al. [52] 301 
did not discuss product recovery. Fig. 2a,b shows the comparison between raw and processed PVP 302 
obtained from run #4. It is clear that there is a decrease in particle size and a narrowing of the particle 303 
size distribution after SAS processing.  304 
Curcumin was then processed at the same conditions used for PVP. The solubility of curcumin in 305 
acetone was estimated to be around 58 mg/ml, while in ethanol it was below 5 mg/ml. In the 306 
experiment with pure ethanol (run #5), a concentration of 2 mg/ml was used; however no powder 307 
could be recovered. When curcumin was processed by a 50-50 Ac-EtOH solution (run #6) and by 308 
pure acetone (run #7) at 10 mg/ml, product recovery was 23.4% and 34.8%.  Despite the higher initial 309 
saturation of the ethanol solution in comparison to the acetone solution, when CO2 is present in the 310 
system a co-solvent effect seems to be taking place with ethanol, as already observed for other 311 
systems [54,55]. This explains the lower product recovery when ethanol was used.  The lower 312 
recovery of curcumin produced by similar processes from alcoholic solutions compared to acetone 313 
have also been observed elsewhere [56]. The authors explained that the higher volume expansion and 314 
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consequently more efficient reduction in solvent power are achieved in the case of acetone possibly 315 
leading to higher recovery. In runs #5, #6 and #7, the amount of curcumin retained in the filter 316 
decreased from 56.4% to 48.2% and 33.0%, respectively (Table 1). Fig. 2c shows rod-like crystals of 317 
raw curcumin with a wide size distribution, while curcumin processed by a 50% Ac-EtOH (Fig. 2d, 318 
run #6) and by pure acetone (Fig. 2e, run #7) has an irregular morphology with smaller dimensions. In 319 
Fig. 2 it is also possible to see that PVP and curcumin precipitate in completely different 320 
morphologies when processed at the same conditions. This underlines the complexity of the SAS 321 
process and its compound-dependent characteristic. 322 
# 
p 
(MPa) 
T (°C) 
f 
(ml/min) 
CTOT 
(mg/ml) 
Solvent 
Solvent 
volumetric 
composition 
Ac-EtOH 
drug/polyme
r mass ratio 
Total 
product 
recovery 
(%) 
Curcumin 
recovery 
(%) 
Curcumin 
retained in 
the filter 
(%) 
m.d. (nm) s.d. (nm) Morphology 
1 9.0 40 1 10 EtOH 0-100 pure PVP ≈ 0 - - - - - 
2 9.0 40 1 20 EtOH 0-100 pure PVP ≈ 0 - - - - - 
3 9.0 40 1 10 Ac-EtOH 50-50 pure PVP 2.0 - - - - - 
4 9.0 40 1 10 Ac-EtOH 90-10 pure PVP 87.0 - - 123 27 SMP 
5 9.0 40 1 2 EtOH 0-100 
pure 
curcumin 
≈ 0 ≈ 0 56.4 - - - 
6 9.0 40 1 10 Ac-EtOH 50-50 
pure 
curcumin 
23.4 23.4 48.2 - - - 
7 9.0 40 1 10 Acetone 100-0 
pure 
curcumin 
34.8 34.8 33.0 - - Irregular 
8 9.0 40 1 10 EtOH 0-100 1:3 43.1 45.5 41.4 - - Irregular 
9 12.0 40 1 10 EtOH 0-100 1:3 63.1 68.1 25.5 - - Irregular 
10 9.0 40 1 10 Ac-EtOH 10-90 1:3 58.0 65.3 29.3 327 102 SMP 
11 9.0 40 1 10 Ac-EtOH 30-70 1:3 74.3 76.6 10.2 177 57 SMP 
12 9.0 40 1 10 Ac-EtOH 50-50 1:3 77.6 78.6 6.7 135 36 SMP 
13 9.0 40 1 10 Ac-EtOH 70-30 1:3 87.1 89.0 2.5 96 25 NP 
14 9.0 40 1 10 Ac-EtOH 90-10 1:3 90.0 89.2 0.8 51 12 NP 
15 8.0 40 1 10 Ac-EtOH 70-30 1:3 56.4 59.6 20.8 181 48 SMP 
16 12.0 40 1 10 Ac-EtOH 70-30 1:3 79.1 88.1 6.7 67 17 NP 
17 9.0 35 1 10 Ac-EtOH 70-30 1:3 89.5 94.9 5.0 72 20 NP 
18 9.0 50 1 10 Ac-EtOH 70-30 1:3 76.9 83.7 9.9 176 56 SMP 
19 9.0 40 1 5 Ac-EtOH 70-30 1:3 80.7 88.9 5.6 65 14 NP 
20 9.0 40 1 20 Ac-EtOH 70-30 1:3 80.2 90.5 6.2 117 30 SMP 
21 9.0 40 1 10 Ac-EtOH 50-50 1:10 60.7 60.2 26.3 - - CM 
22 9.0 40 1 10 Ac-EtOH 70-30 1:10 79.7 79.9 5.5 173 76 SMP 
23 9.0 40 1 10 Ac-EtOH 70-30 1:20 69.2 67.9 9.6 205 49 SMP 
24 9.0 40 0.5 10 EtOH 0-100 1:10 34.3 36.1 48.7 - - CM 
25 9.0 40 0.5 10 Ac-EtOH 10-90 1:10 47.6 50.8 24.9 - - CM 
26 9.0 40 0.5 10 Ac-EtOH 70-30 1:10 79.7 82.3 4.0 220 85 SMP 
 323 
Table 1. Experimental conditions and results (p = pressure; f = solution flow rate; CTOT = total solute 324 
concentration; m.d.: mean diameter; s.d.: standard deviation; SMP: sub-microparticles; NP: 325 
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nanoparticles; CM: coalescing material). Experiments performed at 40°C and CO2 flow rate of 40 326 
g/min. 327 
 328 
 329 
Fig. 2. SEM images of: a) raw PVP; b) PVP processed by SAS (run #4); c) raw curcumin; d) 330 
curcumin processed by SAS from 50% Ac-EtOH (run #6); e) curcumin processed by SAS from 331 
acetone (run #7). 332 
3.2. Coprecipitation of CURC/PVP 333 
It has been demonstrated elsewhere that PVP can interfere in the crystallisation kinetics of some 334 
compounds by inhibiting the association of drug molecules to form crystal nuclei during the solvent 335 
removal from a drug-PVP solution [10,12,57,58]. 336 
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In the second phase of this work, the SAS process was used to produce coprecipitates of curcumin and 337 
PVP and the effect of adjusting the solvation power of the organic solvent, pressure, temperature, 338 
initial solution concentration, mass ratio between drug and polymer and solution flow rate were 339 
explored. Five experiments were run in triplicates and the relative standard deviation of total product 340 
recovery and curcumin recovery was typically below 5%, showing that the conditions were well 341 
controlled. The results shown correspond to the mean values. 342 
3.2.1. Effect of solvent mixture composition 343 
Knowing that the relative composition of acetone in the solvent mixture affects the recovery of PVP 344 
particles, mixtures of acetone-ethanol with increasing acetone volume fraction from 0 to 90% were 345 
used for the coprecipitation experiments (#8-14). Tests were carried out at the same conditions used 346 
for the precipitation of the single compounds (40°C, 9.0 MPa, XCO2 = 0.98 and 10 mg/ml overall 347 
solution concentration) with drug/polymer mass ratio of 1:3. 100% acetone was not used because a 348 
clear solution containing both compounds could not be obtained at the specified concentration. The 349 
effect of adjusting the solution supersaturation through the manipulation of the solvent power, while 350 
keeping the overall solution concentration constant, is demonstrated in this section. Similarities in the 351 
vapour-liquid equilibria of the systems CO2-ethanol and CO2-acetone can be seen in the 352 
supplementary material. 353 
The first interesting result can be seen by comparing run #1 (PVP alone), run #5 (curcumin alone) and 354 
run #8 (coprecipitation) performed at the same conditions with ethanol as solvent. For the single 355 
compounds no powder was obtained, while in the coprecipitation the total product recovery was 356 
43.1%. Similarly, in run #3 (PVP alone) and run #6 (curcumin alone) product recovery was 2% and 357 
23.4%, respectively, increasing to 77.6% in run #12 when the materials were coprecipitated from a 358 
50-50 Ac-EtOH solution (Table 1). These results suggest a synergistic effect in improving the 359 
supersaturation of the solution when both compounds are present and how the presence of two 360 
different solutes can affect the high pressure equilibrium of the system solvent/antisolvent, leading to 361 
different results at the same process conditions. Fig. 3a reveals that two different morphologies, 362 
crystals (curcumin) and irregular particles (PVP), were obtained when pure ethanol was used (run #8), 363 
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indicating that coprecipitation was unsuccessful since the compounds precipitated separately. Particle 364 
size could not be measured. It was considered that this behaviour may be indicative of precipitation 365 
outside of the supercritical region caused by the solutes elevating the critical pressure of the mixture. 366 
To test this, an experiment was performed at 12.0 MPa (run #9), far beyond the critical point of the 367 
system CO2-ethanol (8.16 MPa [51]), to ensure supercritical conditions. Curcumin crystals could still 368 
be seen, as shown in Fig. 3b, suggesting that the separate precipitation is related to something other 369 
than effects on the CO2-ethanol vapour-liquid equilibrium. As the solubility in ethanol of curcumin 370 
and PVP is approximately 5 mg/ml and 315 mg/ml, respectively, the difference in the supersaturation 371 
ratio (initial concentration/solubility) of the two compounds might be so high that simultaneous 372 
precipitation would not be achieved. On the other hand, higher pressure increased product recovery 373 
from 43.1% (run #8) to 63.1% (run #9), suggesting a decrease in the solute solubility in the fluid 374 
phase.  375 
In run #10, the addition of 10% acetone resulted in a successful coprecipitation, as shown in Fig. 3c. 376 
Spherical, largely uniform particles were produced and curcumin rod/filament morphology could no 377 
longer be detected indicating that curcumin is well dispersed in the polymer matrix. A possible reason 378 
for this behaviour may be  that addition of acetone to ethanol simultaneously decreases the solubility 379 
of PVP and increases the solubility of curcumin (as it does at room temperature), leading to more 380 
similar supersaturation ratios of the two solutes when mixed with CO2. The composite material 381 
retained the morphology of the polymer as previously observed in several studies with PVP-drug [33], 382 
demonstrating that the precipitation behaviour is now dominated by PVP. In Fig. 4a it is interesting to 383 
observe the gradual increase in the total product recovery (from 43.1 to 90.0%) and decrease in the 384 
mean particle size of coprecipitates (from 327 to 51 nm) by increasing the acetone content from 0 to 385 
90%. SEM images shown in Fig. 3c,d,e,f,g clearly demonstrates this tendency. The size range 386 
changed from sub-microparticles to nanoparticles and the particle size distribution narrowed (Fig. 4b). 387 
De Marco et al. [24] explained that the variation of the solvent mixture composition can affect the 388 
SAS process in two different ways: by changing the solvation power of the solvent (ability of the 389 
solvent to dissolve the solute at fixed conditions) and/or the mixing behaviour of the injected solution 390 
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with CO2 (large or sharp pressure transition range from two-phase to one-phase mixing). In terms of 391 
mixing regimes, ethanol and acetone have been shown to have similar behaviour (sharp transition 392 
pressure range) [24], therefore the decrease in the mean particle size can be explained by the decrease 393 
in the solvation power as acetone is added to the solvent mixture. Other authors have suggested that 394 
acetone repels the polymer molecules which then tend to be arranged in a more compact 395 
configuration, consequently decreasing particle size [24,53]. The amount of curcumin retained in the 396 
filter gradually decreased from 41.1 to 0.8% as the acetone content increased from 0 to 90% (Table 397 
1). It is not clear why different amounts of material gets trapped in the filter walls at different 398 
operating conditions, hence further investigations will be carried out in future work. Possibly, when 399 
more acetone is present in the system, higher supersaturation can be achieved and the material 400 
precipitates in the first centimetres of the precipitator. The concentration of the fluid phase decreases 401 
and less curcumin is left to nucleate within the thimble walls when passing through it. A decrease in 402 
the degree of particle coalescence was also observed with the addition of acetone, explained by the 403 
fact that acetone experiences a higher volume expansion than alcohols when in contact with sc-CO2 404 
[59,60], being more efficiently removed from the precipitating particles. 405 
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 406 
 407 
Fig. 3. SEM images of CURC/PVP processed from pure ethanol at 40°C, 1.0 ml/min, 1:3 CURC/PVP 408 
ratio and different pressures: a) 9.0 MPa (run #8); b) 12.0 MPa (run #); and samples processed at 9.0 409 
MPa, 40°C, 1.0 ml/min, 1:3 CURC/PVP ratio from different Ac-EtOH compositions: c) 10-90 (run 410 
#10); d) 30-70 (run #11); e) 50-50 (run #12); f) 70-30 (run #13); g) 90-10 (run #14). 411 
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 412 
 413 
 Fig. 4. Results for coprecipitates obtained from solutions with different acetone (Ac) contents at 9.0 414 
MPa and 40°C (run #8, #10-14, Table 1): a) mean diameter and total product recovery; b) particle 415 
size distribution. 416 
 417 
Fig. 5a shows the comparison between curcumin content in the processed samples and in the feed 418 
solutions. For all experiments, the contents before and after processing are similar; therefore the 419 
values of curcumin recovery are close to the respective values of the total product recovery, gradually 420 
increasing from 45.5 (run #8) to 89.2% (run #14) with increasing acetone content. This demonstrates 421 
that the conditions selected are appropriate to precipitate both compounds in the designed proportion 422 
since their proportion was kept almost the same in the feed solution and in the coprecipitated powder. 423 
It is also interesting to observe in Fig. 5b that no degradation of curcumin occurred after SAS 424 
processing. Curcumin retention time (highest peak) was around 7.6 minutes with impurities being 425 
detected slightly before (small peak). By comparing the area of the peaks, curcumin concentration 426 
was determined to be around 90% in all samples (raw curcumin, #6 and #13). As it is not the aim of 427 
this work, the nature of the impurities was not determined, however curcumin is known to be found 428 
with other two curcuminoids (demethoxycurcumin, and bis-demethoxycurcumin) in turmeric extracts 429 
which have been analysed in many works elsewhere [40,61–63].  430 
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 431 
 432 
Fig. 5. a) Curcumin content as fraction of the total solute in the feed solutions and SAS-processed 433 
samples analysed by UV-visible spectrophotometer; b) HPLC measurements of raw curcumin and 434 
processed samples. Experiment conditions are shown in Table 1. 435 
 436 
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The effect of solvent can also be analysed in runs #21-22 (Fig. 6a,b) performed at 1:10 CURC/PVP 437 
ratio and runs #24-26 (Fig. 6d,e,f) performed at 1:10 CURC/PVP ratio and 0.5 ml/min. Similar trends 438 
as runs #10-14 were observed in terms of total product recovery, curcumin recovery (Table 1) and 439 
particle size (Fig. 6), supporting the discussion previously presented. As curcumin recovery did not 440 
increase for acetone content higher than 70% (Table 1), a 70-30 Ac-EtOH solution was selected in 441 
order to analyse the effect of other operational parameters on particle size and recovery. Moreover, 442 
30% of ethanol gives flexibility to work with large amounts of PVP. Therefore, the next experiments 443 
will be compared with run #13, analysing the effect of pressure, temperature and initial solution 444 
concentration. 445 
 446 
23 
 
Fig. 6. SEM images of CURC/PVP processed at 40°C, 9.0 MPa, 1.0 ml/min from different Ac-EtOH 447 
compositions and CURC/PVP ratios: a) 50-50, 1:10 (run #21); b) 70-30, 1:10  (run #22); c) 70-30, 448 
1:20  (run #23); and processed at 0.5 ml/min: d) pure EtOH, 1:10 (run #24); e) 10-90, 1:10 (run #25) 449 
f) 70-30, 1:10 (run #26).     450 
 451 
 452 
Fig. 7. Values of a) mean particle diameter and b) curcumin recovery as a function of the variation of 453 
different operational parameters in comparison with run #13 (centre point). 454 
 455 
3.2.2. Effect of pressure 456 
The effect of pressure was analysed by keeping the operational conditions the same as in run #13 457 
(40°C, 1 ml/min, XCO2 = 0.98, 1:3 CURC/PVP ratio and 10 mg/ml overall solution concentration in a 458 
70-30 Ac-EtOH solution) and changing the pressure from 9.0 MPa to 8.0 MPa (#15) and 12.0 MPa 459 
(#16).  460 
As the critical pressures of the CO2-ethanol and CO2-acetone systems are approximately 8 MPa at 461 
40°C, the operational point in run #15 might be located in the biphasic region. The density of CO2 462 
under these conditions (277.9 kg/m
3 
[64]) is around 43% lower than at 9.0 MPa (485.5 kg/m
3 
[64]). 463 
This lowers the power of CO2 to solubilise the organic solvents and leads to a less effective 464 
supersaturation, which might explain the large increase in particle size from 96 nm (#13) to 181 nm 465 
(run #15, Fig. 8a) and decrease in curcumin recovery from 89.0 (#13) to 59.6% (#15). A high 466 
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proportion (around 21%) of the curcumin injected was retained in the cellulose thimble probably due 467 
to the presence of liquid in the precipitator (operating point in the biphasic region). When the pressure 468 
was increased to 12.0 MPa (#16, Fig. 8b), the CO2 density increased by 48% and the opposite effect 469 
was observed for particle size which decreased to 67 nm. While product recovery (curcumin + PVP, 470 
79.1%) was lower than at 9.0 MPa, curcumin recovery was not much affected, indicating that at 471 
higher pressure the precipitation of PVP is less favourable. Fig. 7 illustrates how the mean particle 472 
diameter of coprecipitates and curcumin recovery varies from the central experiment (#13) as a 473 
function of the variation in the CO2 density with pressure and other operational parameters, which 474 
will be discussed in the following sections. 475 
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 476 
Fig. 8. SEM images of CURC/PVP processed at different conditions: a) run #15 (8.0 MPa); b) run 477 
#16 (12.0 MPa); c) run #17 (35°C); d) run #18 (50°C); e) run #19 (5 mg/ml); f) run #20 (20 mg/ml). 478 
The complete set of operational conditions is shown in Table 1. 479 
 480 
3.2.3. Effect of temperature 481 
The effect of temperature was analysed by keeping the operational conditions the same as in run #13, 482 
(9.0 MPa, 1 ml/min, XCO2 = 0.98, 1:3 CURC/PVP ratio and 10 mg/ml overall solution concentration 483 
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in a 70-30 Ac-EtOH solution) which was performed at 40°C, and changing the temperature to 35°C 484 
(#17) and 50°C (#18).  485 
Fig. 8c,d shows the particles obtained at 35°C (#17) and 50°C (#18) measuring 72 and 176 nm, 486 
respectively. At 35°C the density of CO2 is 662.1 kg/m
3
 (36% higher than 485.5 kg/m
3 
at 40°C[64]) 487 
while at 50°C it is equal to 285.0 kg/m
3 
(41% lower than at 40°C). It is interesting to observe in Fig. 488 
7a that similar CO2 density variations from the central experiment (run #13) caused by temperature 489 
and pressure lead to the production of coprecipitates with similar particle sizes. Experiments 490 
performed at high CO2 density (low temperature or high pressure) yielded smaller particles due to the 491 
improved solvation power of CO2, while the opposite happened with a decrease in CO2 density (high 492 
temperature or low pressure). These results demonstrate the relevance of the fluid density in designing 493 
SAS experiments but it is also important to be aware that other parameters such as fluid viscosity and 494 
solute vapour pressure might play a role in determining particle size as the temperature is changed.   495 
Although similar particle sizes were obtained in runs #15 and #18 (low density) and runs #16 and #17 496 
(high density), both changes in pressure had a negative effect on curcumin recovery (Fig. 7b). In 497 
contrast, at 35°C almost all curcumin was recovered, possibly because the vapour pressure and 498 
solubility of curcumin in the fluid phase decreased.  499 
3.2.4. Effect of solution concentration 500 
The effect of concentration was analysed by keeping the operational conditions the same as in run #13 501 
(9.0 MPa, 40°C, 1 ml/min, XCO2 = 0.98, 1:3 CURC/PVP ratio and 70-30 Ac-EtOH solution) and 502 
changing the overall concentration from 10 mg/ml (run #13) to 5 mg/ml (run #19) and 20 mg/ml (run 503 
#20). The same amount of material was delivered to the precipitator but the solution volume was 504 
adjusted (doubled or halved) to obtain the desired concentration.  505 
A low impact on precipitation was observed. In fact, curcumin recovery changed less than 2% as the 506 
concentration was increased or decreased (Fig. 7b). Particle size decreased to 65 nm at lower 507 
concentration (Fig. 8e) and increased to 117 nm at higher concentration (Fig. 8f), also demonstrating 508 
a small influence of concentration (Fig. 7a). Although higher supersaturation occurs in more 509 
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concentrated solutions, particle growth by condensation is also intensified [50], explaining the results 510 
obtained here. 511 
3.2.5. Effect of drug/polymer mass ratio 512 
The effect of CURC/PVP mass ratio was studied by decreasing the ratio from 1:3 (run #13) to 1:10 513 
(run #22) and 1:20 (run #23). All other operating conditions were kept the same as run #13 (9.0 MPa, 514 
40°C, 1 ml/min, XCO2 = 0.98, 10 mg/ml overall solution concentration in a 70-30 Ac-EtOH solution). 515 
In order to keep the overall concentration constant, the decrease in CURC/PVP ratio was achieved by 516 
simultaneously decreasing the concentration of curcumin and increasing the concentration of PVP. 517 
The morphologies of the particles produced at 1:3, 1:10 and 1:20 CURC/PVP ratios are shown in Fig. 518 
3f and Fig. 6b,c, respectively. The results in Table 1 demonstrate a gradual decrease in total product 519 
recovery from 87.1% to 79.7% and 69.2% as CURC/PVP ratio decreased. Similarly, curcumin 520 
recovery decreased (Fig. 7b) since the curcumin content in the processed sample and feed solution 521 
were almost unchanged (Fig. 5a) (the ratio between the drug and polymer remained the same in the 522 
precipitated powder). On the other hand, particle size increased from 96 nm to 173 nm and further to 523 
205 nm in these experiments (Fig. 7a). This behaviour has been reported before for the coprecipitation 524 
of PVP with other APIs [8,9]. Although the overall concentration was kept constant, the increase in 525 
the concentration of the polymer (from 7.5 mg/ml at 1:3 ratio to 9.5 mg/ml at 1:20 ratio) might have 526 
increased the viscosity of the solution, which decreases the nucleation rate and lead to the formation 527 
of larger and more coalescing particles [48,65,66]. It is also important to highlight that an increase in 528 
the concentration of PVP can additionally affect the particle-fluid interfacial tension. This parameter 529 
might significantly influence particle size, as demonstrated by Erriguible et al. [67]. 530 
Runs #12 (Fig. 3e) and #21 (Fig. 6a) performed with 50% Ac-EtOH solution can also be used to 531 
analyse the effect of decreasing the drug/polymer ratio from 1:3 to 1:10. Once again, the same trend 532 
was observed: a decrease in total product recovery and curcumin recovery and increase in particle 533 
size. It was also noticed that at higher PVP concentration more acetone is needed in the solvent 534 
mixture to generate non-coalescing particles. For coprecipitates with 1:3 CURC/PVP ratio, particles 535 
become discrete with 30% acetone (Fig. 3d). However, highly coalescing material is still obtained at 536 
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1:10 ratio (Fig. 6a) when the acetone content was 50% (run #21), which prevented the measurement 537 
of the particle size. The reason for this behaviour might be that by increasing PVP concentration in 538 
the solution, the viscosity of the liquid phase increases, decreasing the supersaturation and nucleation 539 
rate and leading to a less efficient mixing and solvent removal from the particles, as previously 540 
explained. Therefore, the addition of acetone, which is less viscous and poorer solvent to PVP than 541 
ethanol, favours the formation of discrete particles. 542 
3.2.6. Effect of solution flow rate 543 
The effect of solution flow rate was analysed by keeping the operational conditions unchanged (40°C, 544 
9.0 MPa and 10 mg/ml overall solute concentration) and decreasing the solution flow rate to 0.5 545 
ml/min (XCO2 = 0.99) for a 70-30 Ac-EtOH solution and 1:10 CURC/PVP ratio. This CURC/PVP 546 
ratio was selected because the effect of particle coalescence was more pronounce at 1:10 than at 1:3 547 
and therefore we wanted to investigate the possibility of producing discrete particles with higher PVP 548 
content. Run #26 (0.5 ml/min) can be compared to run #22 (1.0 ml/min) as all other operating 549 
conditions were not changed. The SEM image presented in Fig. 6f (run #26) shows the formation of 550 
discrete sub-microparticles compared to the less discrete particles of run #22 (Fig. 6b).  551 
Solution flow rate is supposed to have a minor impact on particle size [50,68,67] since it may cause 552 
two opposite effects in relation to the supersaturation. For instance, a decrease in the solution flow 553 
rate can lead to a less efficient mixing (which decreases the local supersaturation) and it can also 554 
decrease the solvent composition in the fluid phase which decreases the solute solubility and hence 555 
increases the maximum attainable supersaturation. Therefore, lower impact is expected comparing to 556 
other parameters which affect the vapour-liquid phase equilibrium (pressure and temperature) [50]. As 557 
particle size, morphology and product recovery are affected in different extent by these phenomena, it 558 
was observed a small increase in particle size from 173 nm (run #22) to 220 nm (run #26), while 559 
product recovery was not significantly affected, with values close to 80% (Table 1). Particle coalesce 560 
was reduced at lower flow rates possibly due to the fact that there is more time for the precipitating 561 
particles to dry before they collide with each other, as explained by Gokhale et al. [53]. Similar effects 562 
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of the solution flow rate on particle size have been reported elsewhere for the precipitation of PVP 563 
alone by SAS [53].  564 
3.3. X-Ray Diffraction (XRD) 565 
The degree of crystallinity of the samples was analysed by XRD. Fig. 9 shows that curcumin alone 566 
processed by SAS (SAS-CURC, run #7) is less crystalline than raw curcumin (CURC) as the intensity 567 
of the peaks decreased. The physical mixture (PM 1:3) kept all the curcumin characteristic peaks but 568 
with lower heights than raw CURC due to the presence of PVP, which is an amorphous polymer. The 569 
comparison of the PM (1:3) with the coprecipitates shows that amorphous formulations were formed 570 
in all coprecipitates (runs #11, #13, #14).  571 
 572 
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 573 
Fig. 9.  XRD patterns of raw materials and processed samples. Experiment conditions are shown in  574 
Table 1. 575 
3.4. Differential Scanning Calorimetry (DSC) 576 
Differential Scanning Calorimetry (DSC) was used to access the degree of crystallinity of the samples 577 
and possible interactions between curcumin and PVP after processing. Fig. 10 shows a sharp 578 
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endothermic peak corresponding to the melting point of raw curcumin at Tm = 182°C and enthalpy of 579 
fusion of ∆Hf = 130.9 J/g, indicating the crystallinity of the compound. Other works have reported 580 
similar values for the melting point of unprocessed curcumin but fusion enthalpy varying from 93 – 581 
121 J/g [14,16,56,69,70], which can be explained by differences in the purity of the sample, not 582 
always specified, and differences in the crystal form. PVP, on the other hand, does not show any 583 
melting point peak, demonstrating its amorphous structure and glass transition at Tg = 150°C 584 
(midpoint of the change in heat capacity). In the physical mixture (PM 1:3) the curcumin 585 
characteristic peak was slightly shifted to lower temperature. This behaviour has been observed by 586 
other researchers and may be attributable to a solvent effect of PVP [14,16]. For the SAS 587 
coprecipitate obtained in run #13, no endothermic peak could be detected in the region of curcumin 588 
melting point which indicates that amorphous curcumin was obtained after SAS processing with PVP, 589 
confirming the XRD results (section 3.3). The presence of a single Tg supports the hypothesis of a 590 
single phase and the decrease in Tg compared to the one of PVP is attributed to the plasticizing effect 591 
of the drug molecularly dispersed in the polymeric matrix [13,71].  592 
 593 
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Fig. 10. DSC thermograms of raw materials and coprecipitate (#13). Experiment conditions are 594 
shown in Table 1. 595 
 596 
3.5. Fourier Transform Infrared Spectroscopy (FTIR) 597 
The infrared spectra of the compounds before and after processing were analysed in order to identify 598 
possible interactions between curcumin and PVP. Fig. 11 shows the results obtained. Raw curcumin 599 
(CURC) presents an absorption band at 3504 cm
-1
 corresponding to O-H stretching vibration. Other 600 
peaks can be identified at 1626 cm
-1
 (C=O, C=C), 1601 cm
-1
 (C=C aromatic), 1427 cm
-1
 (C-O 601 
phenol), 1025 cm
-1
 (C-O-C), 960 cm
-1
 (benzoate trans-CH) and 855 cm
-1
  (C-H aromatic) [39,72]. The 602 
FTIR spectrum of PVP shows a peak at 3466 cm
-1
 assigned to the stretching vibration of O-H and 603 
other peaks at 2883, 1651 and 1284 cm
-1
, corresponding to C-H, C=O and C-N, respectively [10,39]. 604 
 605 
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Fig. 11.  IR spectra of raw materials and processed samples. Experiment conditions are shown in 606 
Table 1. 607 
The spectrum of the physical mixture (PM 1:3) is similar to the addition of the individual spectra of 608 
curcumin and PVP, which indicates that no interaction between them has occurred. On the other hand, 609 
for the samples of CURC/PVP processed by SAS (#10, #13, #22, #23), the O-H characteristic peak 610 
(3504 cm
-1
) from curcumin has disappeared. This can be ascribed to an intermolecular interaction, 611 
such as hydrogen bonding, between the O-H of curcumin and the C=O of PVP [16]. This behaviour is 612 
compatible with the observations of other researchers [16,39,73,74] and might explain the change in 613 
the structure of curcumin from crystalline to amorphous (sections 3.3 and 3.4) and the improvement in 614 
the aqueous apparent solubility (section 3.6) and dissolution properties of curcumin formulations 615 
(section 3.7). 616 
3.6. Drug apparent solubility 617 
The apparent solubility of raw curcumin (CURC), SAS-processed curcumin (SAS-CURC, #7), 618 
CURC/PVP physical mixtures (PM) and SAS coprecipitates was determined in water at 25°C. 619 
Unprocessed curcumin has not shown any absorbance at these conditions, while other authors have 620 
measured 0.006 µg/ml after dissolution for 12h in water [39] and 0.5 µg/ml after dissolved in saline 621 
solution and centrifuged at 12,000 rpm for 10 min (25 °C) [36]. The different conditions and method 622 
used explain the different results obtained. The low water solubility of curcumin is one of the main 623 
causes of its low bioavailability [3].  624 
The apparent solubility of curcumin processed by SAS alone was equal to 0.06 µg/ml, which is still 625 
very low. The addition of PVP was found to improve curcumin apparent solubility in the physical 626 
mixtures. 0.3 µg/ml was measured in the mixture at 1:3 CURC/PVP, while 4.4 µg/ml was obtained at 627 
1:10 ratio. This might be explained by a possible decrease in the surface tension of water in the 628 
presence of PVP, which enhances the wetting of the curcumin crystal surface [11,65].  629 
CURC/PVP coprecipitates were produced in an attempt to further increase curcumin apparent 630 
solubility. The apparent solubility of raw CURC, physical mixtures and curcumin formulations are 631 
presented in Fig. 12a. In runs #11 and #13 the apparent solubility increased around 100 times 632 
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compared with the physical mixture (1:3), while in run #14 an increase of more than 600 times was 633 
obtained.  By decreasing CURC/PVP ratio, this effect was even more remarkable (Fig. 12a). In runs 634 
#22 and #26 the measured values were 369 µg/ml and 474 µg/ml, respectively. Other authors have 635 
also reported an improvement in drug apparent solubility as PVP content increases [74]. This was 636 
attributed to the formation of a water-soluble complex between drug and PVP, which was confirmed 637 
by FTIR test (section 3.5). Chhouk et al. [39] reported a curcumin apparent solubility of 2.34 µg/ml in 638 
a formulation with PVP while Kurniawansyah et al. [37]  obtained the highest value equal to 77.6 639 
µg/ml for a ternary system containing curcumin, PVP and methyl-β-cyclodextrin in a ratio of 1:4:4 at 640 
pH 4.5.  641 
 642 
Fig. 12. a) Apparent solubility and b) dissolution profile of raw curcumin (CURC), physical mixtures 643 
(PM) and processed samples. Experiment conditions are shown in Table 1. 644 
 645 
3.7. In vitro dissolution studies 646 
The dissolution profile of coprecipitates (#13, #23, #26), raw curcumin (CURC), physical mixture 647 
(PM 1:3) and curcumin processed by SAS alone (SAS-CURC, #7) was investigated in water + 0.25% 648 
w/v SDS. The surfactant SDS was added to allow for a shorter dissolution study and minimise the 649 
impact of curcumin degradation in the results. Moreover, when no SDS was used, there was no 650 
discrimination among the release profiles of the raw CURC, PM (1:3) and SAS-CURC (#7) due to 651 
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their absorbance values being too close to the minimum detection limit of the UV-visible 652 
spectrophotometer used (results not shown).  653 
Fig. 12b shows the dissolution profiles for the various samples in water + 0.25% w/v SDS. PM (1:3) 654 
releases faster than raw CURC, which is due to the improvement in curcumin wetting and solubility in 655 
the presence of PVP, as discussed in section 3.6. The release of SAS-CURC (#7) is faster than the 656 
physical mixture (1:3), despite having lower apparent solubility in water (section 3.6), as a result of 657 
the smaller size of the curcumin crystals (Fig. 2c,d). All the coprecipitates analysed dissolved 658 
significantly faster than raw CURC and PM (1:3), with complete release being obtained in the first 10 659 
minutes. In the same period of time, raw CURC, PM (1:3) and SAS-CURC (#7) released only 3.2%, 660 
7.5% and 12.8% of curcumin, respectively. These results, in conjunction with the observations of 661 
particle morphology, thermal behaviour and measurements of curcumin recovery, demonstrate that 662 
coprecipitates with high curcumin content and improved dissolution properties were successfully 663 
produced by SAS. The enhancement in the curcumin dissolution profile can be attributed to the 664 
formation of smaller particles with increased apparent solubility (section 3.6) and reduced crystallinity 665 
compared to raw CURC (section 3.3).  666 
Two mechanisms are suggested to for the precipitation of composite materials: homogeneous 667 
nucleation, which produces a solid mixture in which each particle if formed by only one component; 668 
and heterogeneous nucleation, which generates particles composed of both materials (coprecipitates) 669 
[33]. By the results presented in this work, it is believed that heterogeneous nucleation happened, 670 
leading to the formation of composite particles. In any case, the aim of the work was successfully 671 
achieved, as the dissolution properties of curcumin were significantly improved. 672 
4. Conclusions 673 
In this work, the coprecipitation of curcumin and PVP by SAS was successfully achieved from 674 
different solvent mixtures of acetone and ethanol. The results showed that the composition of the 675 
solvent mixture plays a major role in determining particle size, particle size distribution and curcumin 676 
recovery. Particle size varied from sub-microparticles (327 – 135 nm) to nanoparticles (96 - 51 nm) 677 
and the curcumin recovery increased from 45.5 to 89.2% as the relative composition of acetone in the 678 
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ethanol-acetone mixture was increased. The highest curcumin recovery (95%) was obtained at low 679 
temperature (35°C) for a 70-30 Ac-EtOH solution. It was also observed an improvement in curcumin 680 
apparent solubility of around 600 times compared with the physical mixture and, consequently, a 681 
much faster release. These results are explained by the solid state analyses which have demonstrated 682 
the formation of amorphous curcumin-PVP coprecipitates. 683 
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